Alkem Laboratories Senior VP Rakesh Tripathi Steps Down After 8.7-Year Tenure

Alkem Laboratories , a prominent pharmaceutical company, has announced the resignation of Mr. Rakesh Tripathi, Senior Vice President of Regulated Plant Operations, effective December 8, 2025. This development comes as part of the company's mandatory disclosure under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations.

Key Details of the Resignation

Aspect	Details
Resigning Executive	Mr. Rakesh Tripathi
Position	Senior Vice President - Regulated Plant Operations
Effective Date	December 8, 2025
Reason for Resignation	Personal and family reasons
Tenure at Alkem	8.7 years

Mr. Tripathi, who has been an integral part of Alkem's senior management team, cited personal and family commitments as the primary reasons for his decision to step down. The company acknowledged his valuable contributions during his tenure, which spanned nearly nine years.

Impact and Transition

Alkem Laboratories has not yet announced a successor for the position. The company is likely to initiate a transition process to ensure continuity in the regulated plant operations.

Company's Statement

In its official communication, Alkem Laboratories expressed appreciation for Mr. Tripathi's contributions during his time as a Senior Management Personnel. The company stated, "The Company places on record appreciation for the valuable contributions made by him during his tenure as Senior Management Personnel of the Company."

Regulatory Compliance

This announcement aligns with Alkem Laboratories' commitment to transparency and adherence to regulatory requirements. The disclosure, made under SEBI LODR Regulations, ensures that shareholders and the market are promptly informed of significant changes in senior management.

As Alkem Laboratories navigates this transition, stakeholders will be observing any potential impacts on the company's regulated plant operations and overall strategic direction in the pharmaceutical sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.22%	-0.87%	-1.43%	+12.90%	+2.55%	+91.84%

Alkem Laboratories , a prominent pharmaceutical company, has recently received a Goods and Services Tax (GST) demand order from the Assistant Commissioner, Central Goods Service Tax Division in Dehradun, Uttarakhand. The order, which covers the financial years 2018-2019 to 2022-2023, alleges excess availment of Input Tax Credit by the company.

Details of the GST Demand Order

Particulars	Amount (in Rs.)
GST Demand	27,14,603
Penalty	27,79,266
Total	54,93,869

The total amount demanded by the tax authorities stands at approximately Rs. 54.94 lakh, which includes both the GST demand and the associated penalty.

Company's Response

Alkem Laboratories has stated that it disagrees with the demand order. The company plans to contest the allegations, indicating its intention to take appropriate action, which may include filing an appeal against the order.

Impact on Operations

In its disclosure to the stock exchanges, Alkem Laboratories emphasized that there is no material impact on its financial, operational, or other activities due to this GST demand order. This statement suggests that the company views the amount in question as manageable within the context of its overall operations.

Compliance and Transparency

It's worth noting that Alkem Laboratories promptly disclosed this information to the stock exchanges, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action demonstrates the company's commitment to transparency and adherence to regulatory requirements.

The development comes as a reminder of the ongoing scrutiny faced by companies in the pharmaceutical sector regarding tax compliance. As the matter unfolds, stakeholders will likely keep a close watch on how Alkem Laboratories addresses this tax issue and its potential implications on the company's financial statements in the coming quarters.